Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, Evobrutinib in RMS18.10.2018 09:52:48 CEST | Pressemelding
First Bruton’s Tyrosine Kinase inhibitor (BTKi) demonstrating clinical proof-of-concept in relapsing multiple sclerosis (RMS). Study met primary endpoint demonstrating significant reduction in Gd+ enhancing T1 lesions on MRI with evobrutinib versus placebo. Clinically meaningful decrease in annual relapse rates observed.